Maven Securities LTD Purchases New Shares in Candel Therapeutics, Inc. (NASDAQ:CADL)

Maven Securities LTD acquired a new stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 51,731 shares of the company's stock, valued at approximately $449,000. Maven Securities LTD owned 0.16% of Candel Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in shares of Candel Therapeutics during the 4th quarter worth $30,000. Russell Investments Group Ltd. increased its stake in Candel Therapeutics by 75.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company's stock valued at $33,000 after purchasing an additional 1,610 shares in the last quarter. Wells Fargo & Company MN increased its stake in Candel Therapeutics by 63.6% in the 4th quarter. Wells Fargo & Company MN now owns 10,122 shares of the company's stock valued at $88,000 after purchasing an additional 3,935 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Candel Therapeutics by 15.2% in the 4th quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company's stock valued at $90,000 after purchasing an additional 1,375 shares in the last quarter. Finally, LPL Financial LLC purchased a new stake in shares of Candel Therapeutics in the 4th quarter worth about $93,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CADL has been the topic of several recent research reports. Citigroup initiated coverage on shares of Candel Therapeutics in a research report on Thursday, February 20th. They issued a "buy" rating and a $25.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on shares of Candel Therapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, February 26th. Bank of America initiated coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They issued a "buy" rating and a $15.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $19.00 price objective on shares of Candel Therapeutics in a research report on Friday, April 11th.

Insider Buying and Selling at Candel Therapeutics

In related news, insider Charles Schoch sold 5,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.83, for a total transaction of $44,150.00. Following the transaction, the insider now directly owns 38,038 shares in the company, valued at $335,875.54. This trade represents a 11.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Seshu Tyagarajan sold 31,278 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.82, for a total value of $275,871.96. Following the completion of the sale, the chief technology officer now owns 85,512 shares in the company, valued at $754,215.84. The trade was a 26.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. 16.60% of the stock is owned by corporate insiders.

Candel Therapeutics Price Performance

NASDAQ:CADL traded down $0.07 on Monday, reaching $5.29. The stock had a trading volume of 405,926 shares, compared to its average volume of 1,461,755. The company has a market cap of $260.39 million, a price-to-earnings ratio of -3.05 and a beta of -0.92. The firm's fifty day moving average is $5.75 and its two-hundred day moving average is $6.67. Candel Therapeutics, Inc. has a 12-month low of $3.79 and a 12-month high of $14.60.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.37. As a group, research analysts forecast that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.